New dialyser aims to cut blood thinner risks for kidney patients

NCT ID NCT06281028

Completed Disease control Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two dialysis filters, SOLACEA-H and HYDROLINK-NVU, to see if SOLACEA-H can allow dialysis sessions with less or no blood thinner (heparin). The trial involves 20 adults who have been on dialysis for at least 3 months and are medically stable. Each participant will try both filters in sequence, gradually reducing blood thinner doses to find the minimum effective amount.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SOLACEA-H dialyser
What this could lead to: If successful, this dialyser could allow safer dialysis for patients at high risk of bleeding by reducing the need for blood thinners.
What could go wrong: This is a small, early-stage study with only 20 participants, so results may not apply to all dialysis patients. The device may not work as well as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIALYSIS MEMBRANE REACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIALYSIS MEMBRANE REACTION

Contacts and locations

Locations

Hôpital Privé La Louvière

Lille, 59800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.